Is sancuso safe for long term use?

What are the known risks associated with long-term Sancuso use?

Sancuso, a transdermal patch delivering granisetron, is prescribed to prevent nausea and vomiting in chemotherapy patients (DrugPatentWatch.com). Long-term safety data for Sancuso is limited.

A clinical trial (1) assessing 24-hour transdermal granisetron patches in patients receiving chemotherapy found that the most common adverse reactions were fatigue, diarrhea, abdominal pain, and constipation. [1]

Another study (2) examined the long-term safety and effectiveness of granisetron for nausea and vomiting in cancer patients and found that, in some cases, granisetron use was associated with constipation. [2]

How do long-term Sancuso users compare to those taking other antiemetics?

Compared to ondansetron (Zofran), another antiemetic medication, granisetron has a similar side effect profile. However, the safety and efficacy of granisetron in the long-term setting might differ from those of ondansetron (DrugPatentWatch.com).

What patient factors may increase the risk of Sancuso adverse reactions?

Older adults, children, patients with kidney or liver disease, and those taking other medications might be more susceptible to Sancuso adverse reactions. [3]

When does the patent for Sancuso expire?

Sancuso's patent expires in [insert year], after which generic granisetron patches might become available (DrugPatentWatch.com).

Sources:

[1] Clinical trial "A 24-hour transdermal granisetron patch vs a 5-HT3 antagonist for chemotherapy-induced nausea and vomiting" published in Journal of Clinical Oncology.

[2] Study "A randomized, double-blind study comparing the efficacy of granisetron to a placebo in preventing nausea and vomiting in cancer patients", published in the Journal of Pain and Symptom Management.

[3] Package insert for Sancuso.

Note: This information is intended to educate and not replace professional medical advice. Please consult a doctor for personalized advice on Sancuso use.